Haemonetics Beheer
Beheer criteriumcontroles 3/4
De CEO Haemonetics is Chris Simon, benoemd in May2016, heeft een ambtstermijn van 8.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 11.55M, bestaande uit 9.4% salaris en 90.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.54% van de aandelen van het bedrijf, ter waarde $ 19.76M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 7 jaar.
Belangrijke informatie
Chris Simon
Algemeen directeur
US$11.5m
Totale compensatie
| Percentage CEO-salaris | 9.4% |
| Dienstverband CEO | 8.5yrs |
| Eigendom CEO | 0.5% |
| Management gemiddelde ambtstermijn | 3.3yrs |
| Gemiddelde ambtstermijn bestuur | 7yrs |
Recente managementupdates
Recent updates
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
Aug 14Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Jul 18Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Apr 30Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains
Aug 09Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors
Aug 09An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued
Jul 25Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?
Mar 19Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Feb 16Haemonetics: Earnings Rate Of Change Justifies High Multiples
Feb 01We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?
Dec 15Haemonetics Q2 2023 Earnings Preview
Nov 04Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy
Sep 06Haemonetics reaches new 52-week high; shares up 41% YTD
Aug 24Haemonetics reports Q2 earnings beat; raises FY22 guidance
Aug 10A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)
Aug 10Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly
Jul 03Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 29 2024 | n/a | n/a | US$115m |
| Mar 30 2024 | US$12m | US$1m | US$118m |
| Dec 30 2023 | n/a | n/a | US$127m |
| Sep 30 2023 | n/a | n/a | US$128m |
| Jul 01 2023 | n/a | n/a | US$137m |
| Apr 01 2023 | US$11m | US$1m | US$115m |
| Dec 31 2022 | n/a | n/a | US$96m |
| Oct 01 2022 | n/a | n/a | US$86m |
| Jul 02 2022 | n/a | n/a | US$68m |
| Apr 02 2022 | US$9m | US$945k | US$43m |
| Jan 01 2022 | n/a | n/a | US$23m |
| Oct 02 2021 | n/a | n/a | US$31m |
| Jul 03 2021 | n/a | n/a | US$64m |
| Apr 03 2021 | US$9m | US$963k | US$79m |
| Dec 26 2020 | n/a | n/a | US$108m |
| Sep 26 2020 | n/a | n/a | US$106m |
| Jun 27 2020 | n/a | n/a | US$96m |
| Mar 28 2020 | US$9m | US$937k | US$77m |
| Dec 28 2019 | n/a | n/a | US$80m |
| Sep 28 2019 | n/a | n/a | US$68m |
| Jun 29 2019 | n/a | n/a | US$49m |
| Mar 30 2019 | US$9m | US$894k | US$55m |
| Dec 29 2018 | n/a | n/a | US$46m |
| Sep 29 2018 | n/a | n/a | US$21m |
| Jun 30 2018 | n/a | n/a | US$23m |
| Mar 31 2018 | US$8m | US$858k | US$46m |
Compensatie versus markt: De totale vergoeding ($USD 11.55M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.65M ).
Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Chris Simon (60 yo)
8.5yrs
Tenure
US$11,545,113
Compensatie
Mr. Christopher A. Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016 and has been its Director since May 2016. He joined Haemoneti...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 8.5yrs | US$11.55m | 0.54% $ 19.8m | |
| CFO, Executive VP & Financial Officer | 2.6yrs | US$3.15m | 0.0093% $ 340.6k | |
| Executive VP | 7.7yrs | US$3.07m | 0.038% $ 1.4m | |
| Executive Vice President of Global Manufacturing & Supply Chain | 6.3yrs | US$2.43m | 0.038% $ 1.4m | |
| VP, Chief Accounting Officer & Principal Accounting Officer | 2.1yrs | geen gegevens | 0.00027% $ 9.9k | |
| Senior Director of Investor Relations | 5.1yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Strategy & Corporate Development | 1.6yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Human Resources Officer | 3.3yrs | geen gegevens | 0.023% $ 839.9k | |
| Senior VP & Chief Medical Officer | 1.6yrs | geen gegevens | geen gegevens | |
| President of Global Hospital | 5.2yrs | US$2.48m | 0.036% $ 1.3m | |
| Senior Vice President of Global Quality Assurance | 3.3yrs | geen gegevens | geen gegevens | |
| President of Global Plasma & Blood Center | 2.1yrs | geen gegevens | 0.0024% $ 89.6k |
3.3yrs
Gemiddelde duur
53.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van HAE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 8.2yrs | US$11.55m | 0.54% $ 19.8m | |
| Independent Director | 7.1yrs | US$295.73k | 0.035% $ 1.3m | |
| Independent Director | 4.6yrs | US$283.73k | 0.016% $ 591.2k | |
| Independent Chairman | 6.8yrs | US$449.98k | 0.024% $ 875.4k | |
| Independent Director | 5.6yrs | US$269.95k | 0.019% $ 696.5k | |
| Independent Director | 18.8yrs | US$280.73k | 0.032% $ 1.2m | |
| Independent Director | 10.3yrs | US$292.95k | 0.035% $ 1.3m | |
| Independent Director | 3.3yrs | US$272.95k | 0.011% $ 415.2k | |
| Member of Scientific Advisory Council | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Council | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Council | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Council | no data | geen gegevens | geen gegevens |
7.0yrs
Gemiddelde duur
70yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van HAE wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).